CardioVascular Institute Trial Provides Treatment for Left-Sided Heart Failure - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CardioVascular Institute Trial Provides Treatment for Left-Sided Heart Failure


CardioVascular Institute Trial Provides Treatment for Left-Sided Heart Failure

PR Newswire

HARRISBURG, Pa., July 15, 2014 /PRNewswire/ -- Following a heart attack, many heart failure patients suffer from enlargement of their left ventricle, diminishing the amount of blood the heart can pump to the body and resulting in life-threatening left-sided heart failure symptoms such as shortness of breath, decreased urine production, fatigue, and irregular or rapid heartbeat. Treatment options for patients whose left ventricle has enlarged have been limited, until now. Through a percutaneous (needle-puncture of the skin) procedure now available through a clinical trial at PinnacleHealth CardioVascular Institute the first minimally invasive catheter-based device aims to restore normal geometry and function in the damaged muscle (left ventricle). The device is called Parachute® and is created by CardioKinetix in California.

Brijeshwar Maini, M.D., FACC, Director, Structural Heart and Advanced Cardiovascular Interventions at the PinnacleHealth
               CardioVascular Institute serves as principal investigator for the PARACHUTE IV trial.

The PARACHUTE IV clinical trial will enroll 560 patients with left ventricular (LV) systolic dysfunction in 80 hospitals across the country. The procedure, which takes approximately 75 minutes, is performed in a catheterization laboratory setting and patients are under conscious sedation (rather than general anesthesia). The Parachute® implant partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment.

Brijeshwar Maini, M.D., FACC, Director, Structural Heart and Advanced Cardiovascular Interventions at the PinnacleHealth CardioVascular Institute, serves as principal investigator for the PARACHUTE IV trial. "This unique device allows us to provide new options for our heart failure patients," said Dr. Maini. "We are fortunate to have access to this leading edge technology right here in Harrisburg."

"Access to the Parachute® is another key milestone for heart failure patients in central Pennsylvania," said Phil Guarneschelli, Senior Vice President and Chief Operating Officer of PinnacleHealth. "Through PinnacleHealth CardioVascular Institute, our physicians continue to innovate care every day for our community."                    

About PinnacleHealth System

PinnacleHealth is a pioneer not-for-profit healthcare system dedicated to providing and improving the health and quality of life for the people of Central Pennsylvania since 1873. A proven leader in medical innovation, PinnacleHealth offers a wide range of services from primary care to the most complex surgeries and Magnet recognition for nursing excellence. The healthcare network includes four campuses (Community, West Shore, Harrisburg and Polyclinic) and medical services, including family practice, imaging, outpatient surgery and oncology, at multiple locations throughout the region. For a complete list of services, visit our website at www.pinnaclehealth.org.

About CardioKinetix

CardioKinetix, based in Menlo Park, Calif., is pioneering the catheter-based Parachute® Ventricular Partitioning Device for heart failure. Privately held, the company is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Archer Ventures, Panorama Capital, H&Q Healthcare Investors and H&Q Life Sciences Investors. For more information please visit www.cardiokinetix.com.

CONTACT:
Kelly McCall
Public Relations Coordinator
PinnacleHealth System
409 S. Second Street, Suite 1A
PO Box 8700
Harrisburg, PA 17105-8700
717-231-8104 (office)
717-576-2520 (cell)
kmccall@pinnaclehealth.org

Photo - http://photos.prnewswire.com/prnh/20140711/126370

SOURCE PinnacleHealth System

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here